The successful meeting of the primary endpoint for Lumateperone 42 mg as an adjunctive therapy to antidepressants is a significant positive development for Intra-Cellular. This outcome is likely to increase investor confidence in the company's pipeline and could lead to increased demand for ITCI shares in the short term. Positive clinical trial results often lead to an uptick in stock prices for biopharmaceutical companies due to the potential for increased revenue and market share.